🔴 Biomea Fusion is trading 30.2% down in pre-market with BMF-650 results a possible catalyst

Biomea Fusion is trading 30.2% lower at $0.88 after preliminary October 13 Phase 1 results for oral obesity candidate BMF-650, a possible catalyst, though reporting does not link them to the pre-market decline. - First four cohorts: 1.5%–3.2% mean weight reduction; separate, confined fifth cohort: 6.1% over four weeks. - Preliminary, short-term results; the company said the fifth cohort should be interpreted separately because confinement appeared to affect eating behavior. Broad index futures were modestly higher.